This week in techniques

Approach	Summary	Licensing status	Publication and contact information
Drug platforms			
Mammalian cell-based discovery of high-affinity human antibodies from IgG libraries	<p>A human cell line-based platform could be used to generate high-affinity human antibodies from immunologically diverse IgG libraries. The platform used multiple rounds of selection, somatic hypermutation and affinity maturation to identify a lead antibody against nerve growth factor (NGF). In human cell lines, the antibody caused dose-dependent inhibition of NGF binding to its receptor and to the NGF antibody tanezumab. AnaptysBio Inc. has already used the platform to identify ANB004, a human mAb against IL-17. AnaptysBio has ANB004 and the anti-NGF mAb in preclinical development to treat autoimmune indications and pain, respectively. Tanezumab (PF-4383119), a humanized mAb against NGF from Pfizer Inc., is in Phase III testing to treat pain.</p> <p>SciBX 4(48); doi:10.1038/scibx.2011.1365 Published online Dec. 15, 2011</p>	Patented by MRC Laboratory of Molecular Biology and Albert Einstein College of Medicine of Yeshiva University; licensed to AnaptysBio	<p>Bowers, P.M. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Dec. 7, 2011; doi:10.1073/pnas.1114010108 Contact: Peter M. Bowers, AnaptysBio Inc., San Diego, Calif. e-mail: pbowers@anaptysbio.com</p>